	US 12,274,688 B2
	Drug-loaded mesoporous silica nanoparticle for prevention and treatment of brain cancers or brain metastases
Cheng-Hsun Wu, Hsinchu County (TW); Si-Han Wu, Taoyuan (TW); Rong-Lin Zhang, Pingtung County (TW); Chung-Yuan Mou, Taipei (TW); and Hardy Wai Hong Chan, New Taipei (TW)
Assigned to NANO TARGETING & THERAPY BIOPHARMA INC., Taipei (TW); and SCINOPHARM TAIWAN LTD., Tainan (TW)
Filed by NANO TARGETING & THERAPY BIOPHARMA INC, Taipei (TW); and SCINOPHARM TAIWAN LTD., Tainan (TW)
Filed on Oct. 13, 2022, as Appl. No. 17/965,220.
Claims priority of provisional application 63/309,119, filed on Feb. 11, 2022.
Prior Publication US 2023/0255926 A1, Aug. 17, 2023
Int. Cl. A61K 31/337 (2006.01); A61K 9/51 (2006.01); A61K 31/495 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)

CPC A61K 31/337 (2013.01) [A61K 9/5115 (2013.01); A61K 31/495 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01)]

10 Claims

1. A method of treating a brain cancer or brain metastasis in a subject, comprising intravenously administering to the subject a mesoporous silica nanoparticle loaded with a taxane-based chemotherapeutic drug within its pores, wherein:

the taxane-based chemotherapeutic drug is selected from the group consisting of cabazitaxel (CTX) and docetaxel (DTX), and

the mesoporous silica nanoparticle has the following characteristics:

(a) surface modification with (i) an organic molecule, oligomer or polymer and (ii) a positively charged molecule, oligomer or polymer, wherein the molar ratio of (i) and (ii) ranges from 60:1 to 4:1; and

(b) pore internal surface modification with a terminal hydrocarbyl moiety.